论文部分内容阅读
目的:研究低分子肝素钙与肾炎康复片联合治疗原发性肾病综合征的临床效果。方法:选取2013年6月-2014年7月间在我院接受治疗的104例原发性肾病综合征患者,将其随机分为2组,观察组与对照组各有患者52例,给予观察组患者低分子肝素钙与肾炎康复片进行治疗,给予对照组患者低分子肝素钙进行治疗,比较两组患者治疗效果。结果:观察组原发性肾病综合征患者与对照组原发性肾病综合征患者在24 h尿蛋白定量(24 h PRO)、血白蛋白(ALB)、空腹血糖(FBG)、血液粘度(ηp)、总胆固醇(TC)、甘油三酯(TG)方面的各项数据相比,观察组均显著优于对照组,数据有统计学意义差异(P<0.05)。观察组原发性肾病综合征患者治疗总有效率为92.31%;对照组原发性肾病综合征患者治疗总有效率为76.92%,数据差异有统计学意义(χ2=4.7273,P=0.0296),结论:低分子肝素钙联合肾炎康复片对原发性肾病综合征患者的治疗效果较好。
Objective: To study the clinical effect of low molecular weight heparin calcium and nephritis kang tablet in the treatment of primary nephrotic syndrome. Methods: A total of 104 patients with primary nephrotic syndrome who were treated in our hospital from June 2013 to July 2014 were randomly divided into two groups: 52 cases in each group and 52 cases in the control group Group of patients with low molecular weight heparin and nephritis rehabilitation tablets for treatment, given the control group of patients with low molecular weight heparin treatment, the treatment effect of two groups were compared. Results: The patients with primary nephrotic syndrome in the observation group had significant difference in 24 h urinary protein (ALB), fasting plasma glucose (FBG), blood viscosity (ηp ), Total cholesterol (TC) and triglyceride (TG) in the observation group were significantly better than the control group, the data were statistically significant differences (P <0.05). The total effective rate of patients with primary nephrotic syndrome in the observation group was 92.31%. The total effective rate of patients with primary nephrotic syndrome in the control group was 76.92%, the difference was statistically significant (χ2 = 4.7273, P = 0.0296) Conclusion: Low molecular weight heparin combined with nephritis Kangxu tablets in patients with primary nephrotic syndrome treatment is better.